RCS - Trellus Health PLC - Marla Dubinsky a recipient of 2022 Sherman Prize

Trellus HealthAnnouncement

26/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220926:nRSZ5325Aa&default-theme=true

RNS Number : 5325A  Trellus Health PLC  26 September 2022

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Marla Dubinsky named a recipient of 2022 Sherman Prize

 

LONDON, U.K. AND NEW YORK, U.S. (26 September 2022). Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated, resilience-based,
connected health solution for chronic condition management, announces that its
Chief Executive Officer and Co-Founder, Dr. Marla Dubinsky, has been named as
a recipient of the 2022 Sherman Prize.

 

The Sherman Prize is a prestigious national award, each year recognising two
IBD clinicians, surgeons, researchers and/or academics across the United
States with extraordinary track records of achievement, making exceptional and
pioneering contributions that transform IBD care.

 

Dr. Dubinsky has been recognised for her career as an internationally
recognized leader in pediatric IBD, breaking down barriers to help her
youngest patients to regain normal childhoods, as well as her work in
developing the resilience-based methodology at the Mount Sinai IBD Center that
formed the basis of Trellus Health.

 

The 2022 Sherman Prize recipients will be recognized on 6 December 2022,
during the Advances in IBD (AIBD) annual conference.

 

For more information about the Sherman Prize and the other recipient, please
visit: www.shermanprize.org/ (http://www.shermanprize.org/)

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "I am
grateful to have been selected by the selection committee to be a recipient of
this year's Sherman Prize. There are so many clinicians, researchers and
academics across the country who are doing incredible work to better the lives
of those with Crohn's disease and ulcerative colitis, so to be recognized in
this way is a great honor.

 

"Our resilience training provides IBD patients with tools that empower them to
manage adversity so they can create balance in their mind and body. Our
whole-person methodology is something that has previously been missing in the
collective approach to helping patients manage their conditions, and I believe
that Trellus represents a paradigm shift in the way that we support patients
with chronic disease. Our goal is to make this resource available to change
the lives of as many patients as possible, and to help create a world where
every person with a chronic condition has hope and thrives."

 

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Julian Baines, Chairman                                  Via Walbrook PR

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage              Mob: 07980 541 893 / 07748 651 727 / 07867 984 082

 

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first digital health company focused on the
intersection of chronic physical conditions and mental health. Trellus
Health integrates its proprietary resilience-based methodology with the
technology, tools and team to deliver a whole-person technology-enhanced
experience that results in relieving disease burden and promoting individual
health behaviors that enable thriving in the face of a chronic condition.
Through its TrellusElevate™ connected care platform and companion App, the
company addresses both clinical and behavioral health together, in context, to
improve outcomes and reduce healthcare costs for patients, employers, and the
healthcare system.

 

The Company is initially focused on Inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis, but considers its approach to have potential utility and demand
across many chronic conditions, including Irritable Bowel Syndrome ("IBS").

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the GRITT™ methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. This proprietary, resilience-driven
methodology has been scientifically validated to demonstrate meaningful
improvements in patient outcomes, 71% reduction in Emergency Department
(A&E) visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for significant cost
savings for healthcare payers. IBD patients treated using the methodology also
experienced a 49% reduction in required opioid use and a 73% reduction in
corticosteroid use 12 months following program completion (source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) ).

 

The Company was founded by Mount Sinai faculty members Dr. Marla C. Dubinsky,
MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD
and psychogastroenterology, respectively. Trellus Health's patent-pending
GRITT™ resilience assessment and personalized treatment methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGZLRDMGZZG